Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Masanori TokunagaNozomu MachidaJunki MizusawaSeiji ItoHiroshi YabusakiMotohiro HiraoMasaya WatanabeHiroshi ImamuraTakahiro KinoshitaTakushi YasudaJun HiharaHaruhiko FukudaTakaki YoshikawaNarikazu BokuMasanori TerashimaPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)
Trastuzumab can be safely added to platinum-containing doublet chemotherapy as NAC, and it has the potential to contribute to higher antitumor activity against locally advanced, HER2-positive gastric or esophagogastric junction cancer with extensive nodal metastasis.
Keyphrases
- locally advanced
- lymph node metastasis
- papillary thyroid
- squamous cell carcinoma
- neoadjuvant chemotherapy
- rectal cancer
- phase ii study
- radiation therapy
- epidermal growth factor receptor
- minimally invasive
- metastatic breast cancer
- transcription factor
- coronary artery bypass
- palliative care
- squamous cell
- open label
- lymph node
- human health
- risk assessment
- tyrosine kinase
- randomized controlled trial
- climate change
- placebo controlled